AP&T: 与克罗恩病的内镜下黏膜愈合相比,肠道透壁愈合和MRI下愈合与肠道损害进展的风险较低相关

2021-02-19 MedSci原创 MedSci原创

克罗恩病(CD)是炎症性肠病(IBD)的一种亚型,它可能导致患者的生活质量降低和严重生理残疾的发生。

      克罗恩病(CD)是炎症性肠病(IBD)的一种亚型,它可能导致患者的生活质量降低和严重生理残疾的发生。临床缓解是CD治疗的最基本的目标,临床缓解和内镜黏膜愈合的结合是目前CD患者治疗目标,但是实现内镜下黏膜愈合具有更好治疗结果,例如持续时间更长的临床缓解并降低手术或住院风险。但是,需要重复进行结肠镜检查可能会限制这样的指标使用,因此本项研究旨在评估肠壁全层愈合或磁共振成像(MRI)愈合是否比内镜黏膜愈合更好的来预测克罗恩病的长期疗效。

 

 

      研究人员从当地MRI数据库中回顾性地收集了在3个月间隔(中位间隔= 17.5天)内接受MRI和结肠镜检查的所有克罗恩病患者的临床数据。对所有患者进行了四类分组:内窥镜黏膜愈合组(无溃疡或糜烂),MRI愈合组(无MRI炎症迹象),透壁愈合组(内镜和MRI愈合相结合)或无愈合组。主要观察结果是手术时间,肠损伤进展情况,住院时间,和克罗恩病相关的药物停药情况。

 

 

      研究结果显示在154例克罗恩病患者中,无愈合,内镜黏膜愈合,MRI愈合和透壁治疗中分别有51.9%(80/154),10.4%(16/154),19.5%(30/154)和18.2%(28/154)被治愈。透壁愈合(HR = 0.05 [0.00-0.40],P  = 0.002)和MRI愈合(HR = 0.09 [0.00-0.47],P= 0.005)与肠内镜黏膜愈合相比,肠损伤进展的风险较低。此外,与经内镜黏膜愈合相比,实现透壁愈合或MRI愈合降低了发生重大不良结局的风险(HR = 0.28 [0.00-0.74],P = 0.01)。透壁愈合的患者停药复发的风险也降低了(HR = 0.35 [0.13-0.95],P = 0.039)。

 

 

      在研究最后作者说道:与内镜黏膜愈合相比,透壁愈合和MRI愈合与肠道损害进展的风险较低有关,可以被认为是克罗恩病的更好治疗目标。

 

 

 

原始出处 :

Pierre Lafeuille . et al. Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease. Alimentary Pharmacology & Therapeutics.2021.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994924, encodeId=618c19949243d, content=<a href='/topic/show?id=bd3f10325926' target=_blank style='color:#2F92EE;'>#黏膜愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103259, encryptionId=bd3f10325926, topicName=黏膜愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Jan 31 19:38:54 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262228, encodeId=de1a126222823, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Feb 21 01:38:54 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520079, encodeId=404b15200e98b, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Sun Feb 21 01:38:54 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994924, encodeId=618c19949243d, content=<a href='/topic/show?id=bd3f10325926' target=_blank style='color:#2F92EE;'>#黏膜愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103259, encryptionId=bd3f10325926, topicName=黏膜愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Jan 31 19:38:54 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262228, encodeId=de1a126222823, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Feb 21 01:38:54 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520079, encodeId=404b15200e98b, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Sun Feb 21 01:38:54 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994924, encodeId=618c19949243d, content=<a href='/topic/show?id=bd3f10325926' target=_blank style='color:#2F92EE;'>#黏膜愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103259, encryptionId=bd3f10325926, topicName=黏膜愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Jan 31 19:38:54 CST 2022, time=2022-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262228, encodeId=de1a126222823, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Feb 21 01:38:54 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520079, encodeId=404b15200e98b, content=<a href='/topic/show?id=6ab11032506f' target=_blank style='color:#2F92EE;'>#黏膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103250, encryptionId=6ab11032506f, topicName=黏膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057f11309297, createdName=snowpeakxu, createdTime=Sun Feb 21 01:38:54 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-21 snowpeakxu

相关资讯

Dig Dis Sci:新诊断为炎症性肠病的年轻患者的骨密度明显偏低

以溃疡性结肠炎(UC)和克罗恩病(CD)为主的炎症性肠病(IBD)被认为是胃肠道的慢性非特异性炎症。这种情况可能导致营养物质吸收不良,并引起并发症。

Dig Dis Sci:严重缺乏维生素D对炎症性肠病临床病程的影响

克罗恩病(CD)和溃疡性结肠炎(UC)是炎性肠病(IBD)的两种形式,是特发性的慢性复发性疾病,随着IBD在西方和东方国家的普及率不断提高。

Dig Dis Sci: 炎症性肠病不会影响死亡率,但会增加急性心肌梗死患者的住院时间

炎性肠病(IBD)是一种由免疫介导的慢性组织损伤的胃肠道(GI)炎性病症,主要包括溃疡性结肠炎(UC)和克罗恩病(CD)。

IBD:每天服用阿司匹林不会影响炎症性肠病患者的临床疗效

尽管有几项研究已证实非甾体类抗炎药的使用与炎症性肠病(IBD)患者的疾病发作存在相关性,但对每日服用阿司匹林对IBD患者临床结局的影响知之甚少。因此,本项研究旨在对此进行相关评估。

Dig Dis Sci:分娩方式不影响炎症性肠病的风险

以克罗恩病(CD)和溃疡性结肠炎(UC)为主的炎症性肠病(IBD)是胃肠道相关的慢性复发-缓解型炎症性疾病。

TAG:炎症性肠病患者使用维多珠单抗后粪便钙卫蛋白是内镜和组织学缓解的早期预测指标

维多珠单抗-Vedolizumab(VDZ)是一种抑制α4β7整联蛋白的肠道选择性人源化单克隆抗体,目前已经被FDA批准用于治疗溃疡性结肠炎(UC)和克罗恩病(CD)的成年患者。